Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.725 USD | +1.97% | +0.69% | -28.92% |
Apr. 17 | Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board | CI |
Apr. 09 | Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 5.1M |
---|---|---|---|---|---|
Net income 2024 * | -3M | Net income 2025 * | -5M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.69
x | P/E ratio 2025 * |
-3.15
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.44% |
1 day | +1.97% | ||
1 week | +0.69% | ||
Current month | +5.84% | ||
1 month | +5.84% | ||
3 months | -29.61% | ||
6 months | -42.00% | ||
Current year | -28.92% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 67 | 04-12-31 | |
Jonathan Kaufman
CEO | Chief Executive Officer | 58 | 04-12-31 |
Douglas Johnston
DFI | Director of Finance/CFO | 40 | 21-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Kaufman
CEO | Chief Executive Officer | 58 | 04-12-31 |
Founder | 67 | 04-12-31 | |
Byong Kim
BRD | Director/Board Member | 54 | 22-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.725 | +1.97% | 4,066 |
24-04-26 | 0.711 | +0.35% | 4,341 |
24-04-25 | 0.7085 | -0.60% | 4,653 |
24-04-24 | 0.7128 | -0.46% | 6,820 |
24-04-23 | 0.7161 | -0.54% | 10,125 |
Delayed Quote Nasdaq, April 29, 2024 at 04:30 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.92% | 5.1M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.78% | 22.18B | |
-16.67% | 21.2B | |
-8.72% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- LIPO Stock